Media
Artax Biopharma is on a mission to develop new drug candidates which reset the body’s autoimmune system to give normal, healthy responses again in patients with T cell mediated autoimmune diseases.
1 in 10 individuals is affected by autoimmune disease – our mission is to treat them
Autoimmune diseases affect many of us, and we currently lack treatments which restore a more normal autoimmune response without causing immune suppression. Artax Biopharma aims to fill this gap with its pipeline of Nck modulators.
Recent news and publications
-
- Press Releases
Artax Biopharma to present first-in-class Nck modulator mechanism of action and Phase 1 data at the ACR Annual Meeting
Cambridge, MA, October 1, 2024 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on… -
- Press Releases
Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158
AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression. Psoriasis biomarker panel and PASI scores… -
- Press Releases
Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024
Strong support from existing shareholders which includes Lilly, Advent Life Sciences, Columbus Ventures, Sound Bioventures and Belinda Termeer Cambridge,…